Soros Fund Management’s Gyre Therapeutics GYRE Stock Holding History

Soros Fund Management’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-48,409	Closed	-$9.37M	–	222
2018 Q1	$9.37M	Buy	+48,409	New	+$9.03M	0.15%	132
2014 Q3	–	Sell	-18	Closed	-$62K	–	297
2014 Q2	$62K	Buy	+18	New	+$58.7K	﹤0.01%	344

Other funds holding GYRE

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Soros Fund Management's GYRE Position: Q2 2018 in Review

Soros Fund Management sold out of Gyre Therapeutics (GYRE) in Q2 2018, closing a stake of 48,409 shares — an estimated $9.37M sold.

Soros Fund Management first reported a position in GYRE in Q2 2014 and held it in 2 quarters. The position peaked at $9.37M in Q1 2018. 75 funds tracked by Wall St. Rank hold GYRE as of Q2 2018.

Soros Fund Management reported no remaining Gyre Therapeutics position as of Q2 2018 after selling out during the quarter.
Soros Fund Management sold 48,409 Gyre Therapeutics shares in Q2 2018, an estimated $9.37M.
Soros Fund Management first reported a position in Gyre Therapeutics in Q2 2014 and held it in 2 quarters.
Soros Fund Management's Gyre Therapeutics position peaked at $9.37M in Q1 2018.
75 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2018.

Based on Soros Fund Management's 13F filing for Q2 2018, filed 14 Aug 2018.